

7. References

1. Engelhard, M. *et al.* Subclassification of Diffuse Large B-Cell Lymphomas According to the Kiel Classification: Distinction of Centroblastic and Immunoblastic Lymphomas Is a Significant Prognostic Risk Factor. *Blood* **89**, 2291–2297 (1997).
2. Shepherd, P. C. A., Ganesan, T. S. & Galton, D. A. G. Haematological classification of the chronic myeloid leukaemias. *Baillière's Clin. Haematol.* **1**, 887–906 (1987).
3. Bennett, J. M. *et al.* The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia: Proposals by the French - American - British Cooperative Leukaemia Group. *Br. J. Haematol.* **87**, 746–754 (1994).
4. Vardiman, J. W., Harris, N. L. & Brunning, R. D. The World Health Organization (WHO) classification of the myeloid neoplasms. *Blood* **100**, 2292–2302 (2002).
5. Druker, B. J. *et al.* Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome. *N. Engl. J. Med.* **344**, 1038–1042 (2001).
6. Longo, L. *et al.* Rearrangements and aberrant expression of the retinoic acid receptor alpha gene in acute promyelocytic leukemias. *J. Exp. Med.* **172**, 1571–1575 (1990).
7. Tong, J. H. *et al.* Molecular rearrangements of the MYL gene in acute promyelocytic leukemia (APL, M3) define a breakpoint cluster region as well as some molecular variants. *Oncogene* **7**, 311–316 (1992).
8. Hillestad, L. K. Acute promyelocytic leukemia. *Acta Med. Scand.* **159**, 189–194 (1957).
9. Stone, R. M. & Mayer, R. J. The unique aspects of acute promyelocytic leukemia. *J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.* **8**, 1913–1921 (1990).
10. Jeon, I. S. *et al.* A variant Ewing's sarcoma translocation (7;22) fuses the EWS gene to the ETS gene ETV1. *Oncogene* **10**, 1229–1234 (1995).

11. Slamon, D. J. *et al.* Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. *Science* **235**, 177–182 (1987).
12. Slamon, D. J. *et al.* Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. *Science* **244**, 707–712 (1989).
13. Ansari, J., Palmer, D. H., Rea, D. W. & Hussain, S. A. Role of tyrosine kinase inhibitors in lung cancer. *Anticancer Agents Med. Chem.* **9**, 569–575 (2009).
14. Martelli, M. *et al.* Diffuse large B-cell lymphoma. *Crit. Rev. Oncol. Hematol.* **87**, 146–171 (2013).
15. Reddy, A. *et al.* Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma. *Cell* **171**, 481–494.e15 (2017).
16. Klein, U. & Dalla-Favera, R. Germinal centres: role in B-cell physiology and malignancy. *Nat. Rev. Immunol.* **8**, 22–33 (2008).
17. MacLennan, I. C. Germinal centers. *Annu. Rev. Immunol.* **12**, 117–139 (1994).
18. Victora, G. D. & Nussenzweig, M. C. Germinal centers. *Annu. Rev. Immunol.* **30**, 429–457 (2012).
19. Basso, K. & Dalla-Favera, R. Germinal centres and B cell lymphomagenesis. *Nat. Rev. Immunol.* **15**, 172–184 (2015).
20. Schmitz, R. *et al.* Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. *Nature* **490**, 116–20 (2012).
21. De Silva, N. S. & Klein, U. Dynamics of B cells in germinal centres. *Nat. Rev. Immunol.* **15**, 137–148 (2015).
22. Calado, D. P. *et al.* MYC is essential for the formation and maintenance of germinal centers. *Nat. Immunol.* **13**, 1092–1100 (2012).

23. Basso, K. *et al.* Integrated biochemical and computational approach identifies BCL6 direct target genes controlling multiple pathways in normal germinal center B cells. *Blood* **115**, 975–984 (2010).
24. Ci, W. *et al.* The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL. *Blood* **113**, 5536–5548 (2009).
25. Calado, D. P. *et al.* The cell-cycle regulator c-Myc is essential for the formation and maintenance of germinal centers. *Nat. Immunol.* **13**, 1092–1100 (2012).
26. Dominguez-Sola, D. *et al.* The proto-oncogene MYC is required for selection in the germinal center and cyclic reentry. *Nat. Immunol.* **13**, 1083–1091 (2012).
27. EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis | Blood Journal. Available at: <http://www.bloodjournal.org/content/116/24/5247>. (Accessed: 14th September 2017)
28. Heise, N. *et al.* Germinal center B cell maintenance and differentiation are controlled by distinct NF- κ B transcription factor subunits. *J. Exp. Med.* **211**, 2103–2118 (2014).
29. Saito, M. *et al.* A Signaling Pathway Mediating Downregulation of BCL6 in Germinal Center B Cells Is Blocked by BCL6 Gene Alterations in B Cell Lymphoma. *Cancer Cell* **12**, 280–292 (2007).
30. Chu, Y. *et al.* B cells lacking the tumor suppressor TNFAIP3/A20 display impaired differentiation and hyperactivation and cause inflammation and autoimmunity in aged mice. *Blood* **117**, 2227–2236 (2011).
31. Tavares, R. M. *et al.* The Ubiquitin Modifying Enzyme A20 Restricts B Cell Survival and Prevents Autoimmunity. *Immunity* **33**, 181–191 (2010).
32. Klein, U. *et al.* Transcription factor IRF4 controls plasma cell differentiation and class-switch recombination. *Nat. Immunol.* **7**, 773–782 (2006).

33. Sciammas, R. *et al.* Graded Expression of Interferon Regulatory Factor-4 Coordinates Isotype Switching with Plasma Cell Differentiation. *Immunity* **25**, 225–236 (2006).
34. Tunyaplin, C. *et al.* Direct Repression of *prdm1* by Bcl-6 Inhibits Plasmacytic Differentiation. *J. Immunol.* **173**, 1158–1165 (2004).
35. Cobaleda, C., Schebesta, A., Delogu, A. & Busslinger, M. Pax5: the guardian of B cell identity and function. *Nat. Immunol.* **8**, 463–470 (2007).
36. Delogu, A. *et al.* Gene Repression by Pax5 in B Cells Is Essential for Blood Cell Homeostasis and Is Reversed in Plasma Cells. *Immunity* **24**, 269–281 (2006).
37. Nera, K.-P. *et al.* Loss of Pax5 Promotes Plasma Cell Differentiation. *Immunity* **24**, 283–293 (2006).
38. Nutt, S. L., Hodgkin, P. D., Tarlinton, D. M. & Corcoran, L. M. The generation of antibody-secreting plasma cells. *Nat. Rev. Immunol.* **15**, 160–171 (2015).
39. Stevenson, F. K. *et al.* The occurrence and significance of V gene mutations in B cell-derived human malignancy. *Adv. Cancer Res.* **83**, 81–116 (2001).
40. Victora, G. D. *et al.* Identification of human germinal center light and dark zone cells and their relationship to human B-cell lymphomas. *Blood* **120**, 2240–2248 (2012).
41. Dave, S. S. *et al.* Molecular Diagnosis of Burkitt's Lymphoma. *N. Engl. J. Med.* **354**, 2431–2442 (2006).
42. Schmitz, R., Ceribelli, M., Pittaluga, S., Wright, G. & Staudt, L. M. Oncogenic Mechanisms in Burkitt Lymphoma. *Cold Spring Harb. Perspect. Med.* **4**, a014282 (2014).
43. Nussenzweig, A. & Nussenzweig, M. C. Origin of Chromosomal Translocations in Lymphoid Cancer. *Cell* **141**, 27–38 (2010).
44. Dominguez-Sola, D. *et al.* Non-transcriptional control of DNA replication by c-Myc. *Nature* **448**, 445–451 (2007).

45. Corso, J. *et al.* Elucidation of tonic and activated B-cell receptor signaling in Burkitt's lymphoma provides insights into regulation of cell survival. *Proc. Natl. Acad. Sci.* **113**, 5688–5693 (2016).
46. Muppidi, J. R. *et al.* Loss of signalling via Gα13 in germinal centre B-cell-derived lymphoma. *Nature* **516**, 254–258 (2014).
47. McCann, K. J., Johnson, P. W. M., Stevenson, F. K. & Ottensmeier, C. H. Universal N-glycosylation sites introduced into the B-cell receptor of follicular lymphoma by somatic mutation: a second tumorigenic event? *Leukemia* **20**, 530–534 (2006).
48. Alizadeh, a a *et al.* Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. *Nature* **403**, 503–11 (2000).
49. Kridel, R., Sehn, L. H. & Gascoyne, R. D. Pathogenesis of follicular lymphoma. *J. Clin. Invest.* **122**, 3424–3431 (2012).
50. Montoto, S. & Fitzgibbon, J. Transformation of Indolent B-Cell Lymphomas. *J. Clin. Oncol.* **29**, 1827–1834 (2011).
51. Küppers, R. Mechanisms of B-cell lymphoma pathogenesis. *Nat. Rev. Cancer* **5**, 251–62 (2005).
52. Mechanisms of chromosomal translocations in B cell lymphomas. *Publ. Online 10 Sept. 2001 Doi101038sjonc1204640* **20**, (2001).
53. Morin, R. D. *et al.* Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. *Nature* **476**, 298–303 (2011).
54. Pasqualucci, L. *et al.* Analysis of the coding genome of diffuse large B-cell lymphoma. *Nat. Genet.* **43**, 830–837 (2011).
55. Jamroziak, K., Tadmor, T., Robak, T. & Polliack, A. Richter syndrome in chronic lymphocytic leukemia: updates on biology, clinical features and therapy. *Leuk. Lymphoma* **56**, 1949–1958 (2015).

56. Lohr, J. G. *et al.* Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. *Proc. Natl. Acad. Sci. U. S. A.* **109**, 3879–3884 (2012).
57. Pasqualucci, L. *et al.* Inactivating mutations of acetyltransferase genes in B-cell lymphoma. *Nature* **471**, 189–195 (2011).
58. Basso, K. & Dalla-Favera, R. Roles of BCL6 in normal and transformed germinal center B cells. *Immunol. Rev.* **247**, 172–183 (2012).
59. Pasqualucci, L. *et al.* Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphoma. *Blood* **101**, 2914–2923 (2003).
60. Ye, B. H. *et al.* Chromosomal translocations cause deregulated BCL6 expression by promoter substitution in B cell lymphoma. *EMBO J.* **14**, 6209–6217 (1995).
61. Challa-Malladi, M. *et al.* Combined Genetic Inactivation of β 2-Microglobulin and CD58 Reveals Frequent Escape from Immune Recognition in Diffuse Large B Cell Lymphoma. *Cancer Cell* **20**, 728–740 (2011).
62. Boknäs, N. *et al.* Response: Platelets do not generate activated factor XII—how inappropriate experimental models have led to misleading conclusions. *Blood* **124**, 1692–1694 (2014).
63. Aukema, S. M. *et al.* Double-hit B-cell lymphomas. *Blood* **117**, 2319–2331 (2011).
64. Li, S. *et al.* MYC/BCL2 double-hit high-grade B-cell lymphoma. *Adv. Anat. Pathol.* **20**, 315–326 (2013).
65. Béguelin, W. *et al.* EZH2 Is Required for Germinal Center Formation and Somatic EZH2 Mutations Promote Lymphoid Transformation. *Cancer Cell* **23**, 677–692 (2013).
66. Caganova, M. *et al.* Germinal center dysregulation by histone methyltransferase EZH2 promotes lymphomagenesis. *J. Clin. Invest.* **123**, 5009–5022 (2013).

67. Green, J. A. *et al.* The sphingosine 1-phosphate receptor S1P2 maintains the homeostasis of germinal center B cells and promotes niche confinement. *Nat. Immunol.* **12**, 672–680 (2011).
68. Davis, R. E. *et al.* Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. *Nature* **463**, 88–92 (2010).
69. Ngo, V. N. *et al.* Oncogenically active MYD88 mutations in human lymphoma. *Nature* **470**, 115–119 (2011).
70. Compagno, M. *et al.* Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. *Nature* **459**, 717–721 (2009).
71. Lenz, G. *et al.* Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell-like diffuse large B cell lymphoma. *J. Exp. Med.* **204**, 633–643 (2007).
72. Lenz, G. *et al.* Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. *Proc Natl Acad Sci USA* **105**, 13520–13525 (2008).
73. Care, M. A. *et al.* SPIB and BATF provide alternate determinants of IRF4 occupancy in diffuse large B-cell lymphoma linked to disease heterogeneity. *Nucleic Acids Res.* **42**, 7591–7610 (2014).
74. Schmidlin, H. *et al.* Spi-B inhibits human plasma cell differentiation by repressing BLIMP1 and XBP-1 expression. *Blood* **112**, 1804–1812 (2008).
75. Yang, Y. *et al.* Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. *Cancer Cell* **21**, 723–737 (2012).
76. Rosenwald, A., Wright, G., Chan, W. *et al.*, WC, C. & Al., E. The use of molecular profiling to predict survival after chemotherapy for diffuse large B-cell lymphoma. *N. Engl. J. Med.* **346**, 1937–1947 (2002).

77. Bunn, H. F. & Aster, J. C. *Pathophysiology of Blood Disorders*. (McGraw-Hill Education / Medical, 2011).
78. Sehn, L. H. *et al.* The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. *Blood* **109**, 1857–1862 (2015).
79. Savage, K. J. *et al.* MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. *Blood* **114**, 3533–3537 (2009).
80. Ott, G. *et al.* Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL. *Blood* **116**, 4916–4925 (2010).
81. Murase, T. *et al.* Intravascular large B-cell lymphoma (IVLBCL): a clinicopathologic study of 96 cases with special reference to the immunophenotypic heterogeneity of CD5. *Blood* **109**, 478–485 (2007).
82. Swerdlow, S. H. *et al.* The 2016 revision of the World Health Organization classification of lymphoid neoplasms. *Blood* **127**, 2375–2390 (2016).
83. Rosenthal, A. & Younes, A. High grade B-cell lymphoma with rearrangements of MYC and BCL2 and/or BCL6: Double hit and triple hit lymphomas and double expressing lymphoma. *Blood Rev.* **31**, 37–42 (2017).
84. Sesques, P. & Johnson, N. A. Approach to the diagnosis and treatment of high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements. *Blood* **129**, 280–288 (2017).
85. Eberle, F. C. *et al.* Gray zone lymphoma: chromosomal aberrations with immunophenotypic and clinical correlations. *Mod. Pathol. Off. J. U. S. Can. Acad. Pathol. Inc* **24**, 1586–1597 (2011).

86. Traverse-Glehen, A. *et al.* Mediastinal gray zone lymphoma: the missing link between classic Hodgkin's lymphoma and mediastinal large B-cell lymphoma. *Am. J. Surg. Pathol.* **29**, 1411–1421 (2005).
87. Zinzani, P. L. *et al.* Anaplastic large-cell lymphoma: clinical and prognostic evaluation of 90 adult patients. *J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.* **14**, 955–962 (1996).
88. Dunleavy, K. & Wilson, W. H. Primary mediastinal B-cell lymphoma and mediastinal gray zone lymphoma: do they require a unique therapeutic approach? *Blood* **125**, 33–39 (2015).
89. Taddesse-Heath, L., Meloni-Ehrig, A., Scheerle, J., Kelly, J. C. & Jaffe, E. S. Plasmablastic lymphoma with MYC translocation: evidence for a common pathway in the generation of plasmablastic features. *Mod. Pathol. Off. J. U. S. Can. Acad. Pathol. Inc* **23**, 991–999 (2010).
90. Castillo, J. J. Plasmablastic lymphoma: are more intensive regimens needed? *Leuk. Res.* **35**, 1547–1548 (2011).
91. Castillo, J. J. *et al.* Human immunodeficiency virus-associated plasmablastic lymphoma: poor prognosis in the era of highly active antiretroviral therapy. *Cancer* **118**, 5270–5277 (2012).
92. Achten, R., Verhoef, G., Vanuytsel, L. & De Wolf-Peeters, C. Histiocyte-rich, T-cell-rich B-cell lymphoma: a distinct diffuse large B-cell lymphoma subtype showing characteristic morphologic and immunophenotypic features. *Histopathology* **40**, 31–45 (2002).
93. Abramson, J. S. T-cell/histiocyte-rich B-cell lymphoma: biology, diagnosis, and management. *The Oncologist* **11**, 384–392 (2006).

94. Achten, R., Verhoef, G., Vanuytsel, L. & De Wolf-Peeters, C. T-cell/histiocyte-rich large B-cell lymphoma: a distinct clinicopathologic entity. *J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.* **20**, 1269–1277 (2002).
95. Colomo, L. *et al.* Diffuse large B-cell lymphomas with plasmablastic differentiation represent a heterogeneous group of disease entities. *Am. J. Surg. Pathol.* **28**, 736–747 (2004).
96. Valera, A. *et al.* IG/MYC rearrangements are the main cytogenetic alteration in plasmablastic lymphomas. *Am. J. Surg. Pathol.* **34**, 1686–1694 (2010).
97. Oyama, T. *et al.* Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group: a study of 96 patients. *Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res.* **13**, 5124–5132 (2007).
98. Aozasa, K., Takakuwa, T. & Nakatsuka, S. Pyothorax-associated lymphoma: a lymphoma developing in chronic inflammation. *Adv. Anat. Pathol.* **12**, 324–331 (2005).
99. Tomita, N. *et al.* Clinicopathological features of lymphoma/leukemia patients carrying both BCL2 and MYC translocations. *Haematologica* **94**, 935–943 (2009).
100. Nakatsuka, S.-I. *et al.* Pyothorax-associated lymphoma: a review of 106 cases. *J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.* **20**, 4255–4260 (2002).
101. Delsol, G. *et al.* A new subtype of large B-cell lymphoma expressing the ALK kinase and lacking the 2; 5 translocation. *Blood* **89**, 1483–1490 (1997).
102. Gesk, S. *et al.* ALK-positive diffuse large B-cell lymphoma with ALK-Clathrin fusion belongs to the spectrum of pediatric lymphomas. *Leukemia* **19**, 1839–1840 (2005).
103. Laurent, C. *et al.* Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma: a rare clinicopathologic entity with poor prognosis. *J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.* **27**, 4211–4216 (2009).

104. Morgan, E. A. & Nascimento, A. F. Anaplastic lymphoma kinase-positive large B-cell lymphoma: an underrecognized aggressive lymphoma. *Adv. Hematol.* **2012**, 529572 (2012).
105. Bedwell, C. *et al.* Cytogenetically complex SEC31A-ALK fusions are recurrent in ALK-positive large B-cell lymphomas. *Haematologica* **96**, 343–346 (2011).
106. Chabner, B. A. Early accelerated approval for highly targeted cancer drugs. *N. Engl. J. Med.* **364**, 1087–1089 (2011).
107. Delecluse, H. J. *et al.* Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection. *Blood* **89**, 1413–1420 (1997).
108. Vega, F. *et al.* Plasmablastic lymphomas and plasmablastic plasma cell myelomas have nearly identical immunophenotypic profiles. *Mod. Pathol. Off. J. U. S. Can. Acad. Pathol. Inc* **18**, 806–815 (2005).
109. Gabrea, A. *et al.* Secondary genomic rearrangements involving immunoglobulin or MYC loci show similar prevalences in hyperdiploid and nonhyperdiploid myeloma tumors. *Genes. Chromosomes Cancer* **47**, 573–590 (2008).
110. Cesarman, E., Chang, Y., Moore, P. S., Said, J. W. & Knowles, D. M. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. *N. Engl. J. Med.* **332**, 1186–1191 (1995).
111. Cobo, F. *et al.* Expression of potentially oncogenic HHV-8 genes in an EBV-negative primary effusion lymphoma occurring in an HIV-seronegative patient. *J. Pathol.* **189**, 288–293 (1999).
112. Teruya-Feldstein, J. *et al.* Expression of human herpesvirus-8 oncogene and cytokine homologues in an HIV-seronegative patient with multicentric Castleman's disease and

- primary effusion lymphoma. *Lab. Investig. J. Tech. Methods Pathol.* **78**, 1637–1642 (1998).
113. Chadburn, A. *et al.* KSHV-positive solid lymphomas represent an extra-cavitary variant of primary effusion lymphoma. *Am. J. Surg. Pathol.* **28**, 1401–1416 (2004).
114. Petitjean, B. *et al.* Pyothorax-associated lymphoma: a peculiar clinicopathologic entity derived from B cells at late stage of differentiation and with occasional aberrant dual B- and T-cell phenotype. *Am. J. Surg. Pathol.* **26**, 724–732 (2002).
115. Beaty, M. W. *et al.* A biophenotypic human herpesvirus 8--associated primary bowel lymphoma. *Am. J. Surg. Pathol.* **23**, 992–994 (1999).
116. Ahmad, A. *et al.* Kaposi sarcoma-associated herpesvirus-encoded viral FLICE inhibitory protein (vFLIP) K13 cooperates with Myc to promote lymphoma in mice. *Cancer Biol. Ther.* **10**, 1033–1040 (2010).
117. Bubman, D., Guasparri, I. & Cesarman, E. Deregulation of c-Myc in primary effusion lymphoma by Kaposi's sarcoma herpesvirus latency-associated nuclear antigen. *Oncogene* **26**, 4979–4986 (2007).
118. Rodriguez, J. *et al.* Follicular Large Cell Lymphoma: An Aggressive Lymphoma That Often Presents With Favorable Prognostic Features. *Blood* **93**, 2202–2207 (1999).
119. Campo, E. *et al.* The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. *Blood* **117**, 5019–5032 (2011).
120. Matutes, E. *et al.* Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria. *Leukemia* **22**, 487–495 (2008).
121. Thieblemont, C. *et al.* Splenic marginal-zone lymphoma: A distinct clinical and pathological entity. *Lancet Oncol.* **4**, 95–103 (2003).
122. Weill, J.-C., Weller, S. & Reynaud, C.-A. Human marginal zone B cells. *Annu. Rev. Immunol.* **27**, 267–285 (2009).

123. Zibellini, S. *et al.* Stereotyped patterns of B-cell receptor in splenic marginal zone lymphoma. *Haematologica* **95**, 1792–1796 (2010).
124. Over 30% of Patients With Splenic Marginal Zone Lymphoma Express the Same Immunoglobulin Heavy Variable Gene: Ontogenetic Implications. *PubMed Journals* Available at: <https://ncbi.nlm.nih.gov/labs/articles/22222599/>. (Accessed: 14th September 2017)
125. Brisou, G. *et al.* A restricted IGHV gene repertoire in splenic marginal zone lymphoma is associated with autoimmune disorders. *Haematologica* **99**, e197–e198 (2014).
126. Analysis of mutations in immunoglobulin heavy chain variable region genes of microdissected marginal zone (MGZ) B cells suggests that the MGZ of human spleen is a reservoir of memory B cells. *J. Exp. Med.* **182**, 559–566 (1995).
127. Tierens, A., Delabie, J., Michiels, L., Vandenberghe, P. & De Wolf-Peeters, C. Marginal-zone B cells in the human lymph node and spleen show somatic hypermutations and display clonal expansion. *Blood* **93**, 226–234 (1999).
128. Colombo, M. *et al.* Expression of Immunoglobulin Receptors with Distinctive Features Indicating Antigen Selection by Marginal Zone B Cells from Human Spleen. *Mol. Med.* **19**, 294–302 (2013).
129. Du, M.-Q. Pathogenesis of splenic marginal zone lymphoma. *Pathogenesis* **2**, 11–20 (2015).
130. Caro, P. *et al.* Metabolic Signatures Uncover Distinct Targets in Molecular Subsets of Diffuse Large B-Cell Lymphoma. *Cancer Cell* **22**, 547–560 (2012).
131. Smith, A. *et al.* The Haematological Malignancy Research Network (HMRN): a new information strategy for population based epidemiology and health service research. *Br. J. Haematol.* **148**, 739–753 (2010).

132. Wang, H.-I. *et al.* Long-term medical costs and life expectancy of acute myeloid leukemia: a probabilistic decision model. *Value Health J. Int. Soc. Pharmacoeconomics Outcomes Res.* **17**, 205–214 (2014).
133. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows–Wheeler transform. *Bioinformatics* **25**, 1754–1760 (2009).
134. Quinlan, A. R. & Hall, I. M. BEDTools: a flexible suite of utilities for comparing genomic features. *Bioinformatics* **26**, 841–842 (2010).
135. Jones, D. *et al.* cgpCaVEManWrapper: Simple Execution of CaVEMan in Order to Detect Somatic Single Nucleotide Variants in NGS Data. in *Current Protocols in Bioinformatics* (John Wiley & Sons, Inc., 2002). doi:10.1002/cpbi.20
136. Ye, K., Schulz, M. H., Long, Q., Apweiler, R. & Ning, Z. Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads. *Bioinformatics* **25**, 2865–2871 (2009).
137. Ramirez-Gonzalez, R. H., Bonnal, R., Caccamo, M. & MacLean, D. Bio-samtools: Ruby bindings for SAMtools, a library for accessing BAM files containing high-throughput sequence alignments. *Source Code Biol. Med.* **7**, 6 (2012).
138. Donlin, M. J. Using the Generic Genome Browser (GBrowse). in *Current Protocols in Bioinformatics* (John Wiley & Sons, Inc., 2002). doi:10.1002/0471250953.bi0909s28
139. Lek, M. *et al.* Analysis of protein-coding genetic variation in 60,706 humans. *Nature* **536**, 285–291 (2016).
140. Menzies, A. *et al.* VAGrENT: Variation Annotation Generator. in *Current Protocols in Bioinformatics* (John Wiley & Sons, Inc., 2002). doi:10.1002/0471250953.bi1508s52
141. Forbes, S. A. *et al.* COSMIC: exploring the world’s knowledge of somatic mutations in human cancer. *Nucleic Acids Res.* **43**, D805–D811 (2015).
142. Whye, Y. *et al.* Hierarchical Dirichlet. **101**, 1566–1581 (2012).

143. Papaemmanuil, E. *et al.* Genomic Classification and Prognosis in Acute Myeloid Leukemia. *N. Engl. J. Med.* **374**, 2209–2221 (2016).
144. Pasqualucci, L. & Dalla-Favera, R. SnapShot: Diffuse Large B Cell Lymphoma. *Cancer Cell* **25**, 132–132.e1 (2014).
145. Gerstung, M. *et al.* Reliable detection of subclonal single-nucleotide variants in tumour cell populations. *Nat. Commun.* **3**, 811 (2012).
146. Loo, P. V. *et al.* Allele-specific copy number analysis of tumors. *Proc. Natl. Acad. Sci.* **107**, 16910–16915 (2010).
147. Lee, J.-H., Jeong, H., Choi, J.-W., Oh, H. & Kim, Y.-S. Clinicopathologic significance of MYD88 L265P mutation in diffuse large B-cell lymphoma: a meta-analysis. *Sci. Rep.* **7**, 1785 (2017).
148. Bösl, M. W. *et al.* STAT6 Is Recurrently and Significantly Mutated in Follicular Lymphoma and Enhances the IL-4 Induced Expression of Membrane-Bound and Soluble CD23. *Blood* **126**, 3923–3923 (2015).
149. Project, the I. M.-S. Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing. *Nat. Genet.* **44**, 1316–1320 (2012).
150. Campo, E. New pathogenic mechanisms in Burkitt lymphoma. *Nat. Genet.* **44**, 1288–1289 (2012).
151. Yoshimura, A., Naka, T. & Kubo, M. SOCS proteins, cytokine signalling and immune regulation. *Nat. Rev. Immunol.* **7**, 454–465 (2007).
152. Jelinic, P. *et al.* Recurrent SMARCA4 mutations in small cell carcinoma of the ovary. *Nat. Genet.* **46**, 424–426 (2014).
153. Shain, A. H. & Pollack, J. R. The spectrum of SWI/SNF mutations, ubiquitous in human cancers. *PLoS One* **8**, e55119 (2013).

154. Beà, S. *et al.* Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. *Proc. Natl. Acad. Sci. U. S. A.* **110**, 18250–18255 (2013).
155. Camus, V. *et al.* Detection and prognostic value of recurrent XPO1 mutations in tumor and cell-free circulating DNA of patients with classical Hodgkin Lymphoma. *Haematologica* haematol.2016.145102 (2016). doi:10.3324/haematol.2016.145102
156. Pon, J. R. *et al.* MEF2B mutations in non-Hodgkin lymphoma dysregulate cell migration by decreasing MEF2B target gene activation. *Nat. Commun.* **6**, 7953 (2015).
157. Jeelall, Y. S. *et al.* Human lymphoma mutations reveal CARD11 as the switch between self-antigen-induced B cell death or proliferation and autoantibody production. *J. Exp. Med.* **209**, 1907–1917 (2012).
158. Lenz, G. *et al.* Oncogenic CARD11 Mutations in Human Diffuse Large B Cell Lymphoma. *Science* **319**, 1676–1679 (2008).
159. Nikolaev, S. I. *et al.* Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. *Nat. Genet.* **44**, 133–139 (2011).
160. Schmidt, J. *et al.* Mutations of MAP2K1 are frequent in pediatric-type follicular lymphoma and result in ERK pathway activation. *Blood* blood-2017-03-776278 (2017). doi:10.1182/blood-2017-03-776278
161. Levy, D. E. & Lee, C. What does Stat3 do? *J. Clin. Invest.* **109**, 1143–1148 (2002).
162. Xie, T.-X. *et al.* Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis. *Oncogene* **23**, 3550–3560 (2004).
163. Khodabakhshi, A. H. *et al.* Recurrent targets of aberrant somatic hypermutation in lymphoma. *Oncotarget* **3**, 1308–19 (2012).
164. BCL10 gene mutations rarely occur in lymphoid malignancies. *Publ. Online 17 April 2000 Doi101038sjleu2401747* **14**, (2000).

165. Tsushita, K. *et al.* Mutation study of the BCL10 gene in lymphoma with both RNA and DNA. *Leukemia* **15**, 1139–1140 (2001).
166. Turvey, S. E. *et al.* The CARD11-BCL10-MALT1 (CBM) signalosome complex: Stepping into the limelight of human primary immunodeficiency. *J. Allergy Clin. Immunol.* **134**, 276–284 (2014).
167. Yang, C., David, L., Qiao, Q., Damko, E. & Wu, H. The CBM signalosome: Potential therapeutic target for aggressive lymphoma? *Cytokine Growth Factor Rev.* **25**, 175–183 (2014).
168. Rebeaud, F. *et al.* The proteolytic activity of the paracaspase MALT1 is key in T cell activation. *Nat. Immunol.* **9**, 272–281 (2008).
169. Xu, Y. *et al.* Loss of IRF8 Inhibits the Growth of Diffuse Large B-cell Lymphoma. *J. Cancer* **6**, 953–961 (2015).
170. Waight, J. D., Banik, D., Griffiths, E. A., Nemeth, M. J. & Abrams, S. I. Regulation of the interferon regulatory factor-8 (IRF-8) tumor suppressor gene by the signal transducer and activator of transcription 5 (STAT5) transcription factor in chronic myeloid leukemia. *J. Biol. Chem.* **289**, 15642–15652 (2014).
171. Müschen, M., Warskulat, U. & Beckmann, M. W. Defining CD95 as a tumor suppressor gene. *J. Mol. Med. Berl. Ger.* **78**, 312–325 (2000).
172. Villa-Morales, M. *et al.* FAS system deregulation in T-cell lymphoblastic lymphoma. *Cell Death Dis.* **5**, e1110 (2014).
173. Helming, K. C. *et al.* ARID1B is a specific vulnerability in ARID1A-mutant cancers. *Nat. Med.* **20**, 251–254 (2014).
174. Santen, G. W. E. *et al.* Mutations in SWI/SNF chromatin remodeling complex gene ARID1B cause Coffin-Siris syndrome. *Nat. Genet.* **44**, 379–380 (2012).

175. Sausen, M. *et al.* Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma. *Nat. Genet.* **45**, 12–17 (2013).
176. Cajuso, T. *et al.* Exome sequencing reveals frequent inactivating mutations in ARID1A, ARID1B, ARID2 and ARID4A in microsatellite unstable colorectal cancer. *Int. J. Cancer* **135**, 611–623 (2014).
177. Khursheed, M. *et al.* ARID1B, a member of the human SWI/SNF chromatin remodeling complex, exhibits tumour-suppressor activities in pancreatic cancer cell lines. *Br. J. Cancer* **108**, 2056–2062 (2013).
178. Kridel, R. *et al.* Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma. *Blood* **119**, 1963–1971 (2012).
179. Clipson, A. *et al.* KLF2 mutation is the most frequent somatic change in splenic marginal zone lymphoma and identifies a subset with distinct genotype. *Leukemia* **29**, 1177–1185 (2015).
180. Piva, R. *et al.* The Krüppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma. *Leukemia* **29**, 503–507 (2015).
181. Christiaans, I. *et al.* Germline SMARCB1 mutation and somatic NF2 mutations in familial multiple meningiomas. *J. Med. Genet.* **48**, 93–97 (2011).
182. Friedberg, J. W. Double-Hit Diffuse Large B-Cell Lymphoma. *J. Clin. Oncol.* **30**, 3439–3443 (2012).
183. Hwang, Y. Y., Loong, F., Chung, L. P. & Chim, C. S. Atypical burkitt's lymphoma transforming from follicular lymphoma. *Diagn. Pathol.* **6**, 63 (2011).
184. Arcaini, L., Rossi, D. & Paulli, M. Splenic marginal zone lymphoma : from genetics to management. **127**, 2072–2082 (2016).
185. Gao, X. *et al.* High-Grade Transformation in a Splenic Marginal Zone Lymphoma with a Cerebral Manifestation. *Am. J. Case Rep.* **18**, 611–616 (2017).

186. Gerstung, M. *et al.* Precision oncology for acute myeloid leukemia using a knowledge bank approach. *Nat. Genet.* **49**, 332–340 (2017).
187. Pastore, A. *et al.* Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. *Lancet Oncol.* **16**, 1111–1122 (2015).
188. Jurinovic, V. *et al.* Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy. *Blood* **128**, 1112–1120 (2016).
189. Roschewski, M., Staudt, L. M. & Wilson, W. H. Diffuse large B-cell lymphoma-treatment approaches in the molecular era. *Nat. Rev. Clin. Oncol.* **11**, 12–23 (2014).